Sen. Shaheen Calls on FDA to Stop Drug Manufacturer From Abusing System Amid Opioid Epidemic
September 10, 2019
September 10, 2019
WASHINGTON, Sept. 10 -- Sen. Jeanne Shaheen, D-New Hampshire, issued the following news release:
U.S. Senator Jeanne Shaheen (D-NH) sent a letter to the Food and Drug Administration's (FDA) Acting Commissioner Dr. Norman Sharpless, requesting that the FDA prevent the manufacturer of buprenorphine from abusing the FDA's "Orphan Drug Designation" process to secure an additional seven years of market exclusivity. The new monthly injection version of buprenorphine - known as S . . .
U.S. Senator Jeanne Shaheen (D-NH) sent a letter to the Food and Drug Administration's (FDA) Acting Commissioner Dr. Norman Sharpless, requesting that the FDA prevent the manufacturer of buprenorphine from abusing the FDA's "Orphan Drug Designation" process to secure an additional seven years of market exclusivity. The new monthly injection version of buprenorphine - known as S . . .